TrialBMC cancer2022

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.

L de la Cruz-Merino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.